Compare SBLK & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SBLK | PBLS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.6B |
| IPO Year | 2007 | 2026 |
| Metric | SBLK | PBLS |
|---|---|---|
| Price | $27.83 | $23.38 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $34.44 | ★ $41.75 |
| AVG Volume (30 Days) | ★ 1.6M | 1.2M |
| Earning Date | 11-18-2026 | 11-17-2026 |
| Dividend Yield | ★ 5.00% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.73 | N/A |
| Revenue Next Year | N/A | $222.58 |
| P/E Ratio | $47.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.29 | $24.80 |
| 52 Week High | $32.88 | $42.49 |
| Indicator | SBLK | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 34.97 | 27.12 |
| Support Level | $27.15 | N/A |
| Resistance Level | $28.39 | $41.72 |
| Average True Range (ATR) | 0.73 | 2.22 |
| MACD | -0.27 | -0.51 |
| Stochastic Oscillator | 4.52 | 3.88 |
Star Bulk Carriers Corp provides seaborne transportation solutions in the dry bulk sector. The company owns and operates dry bulk carrier vessels, which are used to transport bulk, such as iron ore, coal, grains, bauxite, fertilizers, and steel products. It owns a fleet of vessels that consists of Newcastlemax, Capesize, Post Panamax, Kamsarmax, Panamax, Ultramax, and Supramax. The firm generates the majority of its revenue from Time charters and Voyage charters.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.